Core Insights - The establishment of Meituan's Aesthetic Medicine Upstream Brand Advisory Committee marks a significant step in enhancing collaboration with upstream brands in the aesthetic medicine industry [1][2] - The Chinese aesthetic medicine market is projected to grow from 3,093 billion yuan last year to 7,102 billion yuan by 2031, indicating substantial growth potential [1] - The industry faces serious challenges, including a low authenticity rate of aesthetic medicine injectables at only 35%, leading to significant consumer complaints regarding product quality [1] Group 1 - The newly formed advisory committee will serve to strengthen the partnership between Meituan and upstream brands, aiming for strategic collaboration and innovation in the industry [2] - Meituan has deepened its cooperation with over 100 brands this year, with a goal of covering more than 200 brands, thereby enhancing the balance among platforms, brands, institutions, and users [2] - During the recent "618" shopping festival, the number of upstream cooperative brands on Meituan's platform increased by over 110%, with transaction volume growing nearly 150% [2] Group 2 - The advisory committee is expected to set a benchmark for upstream brands, driving innovation and sustainable development within the industry [2] - Meituan's initiative to launch a "Find Brand" channel aims to connect consumers directly with authorized brand institutions and professional doctors, addressing issues related to counterfeit products [1]